Technology | January 20, 2010

Diagnostic MR Angiography Imaging Agent Introduced

January 20, 2010 – A new contrast-imaging agent for use with magnetic resonance angiography (MRA) is being launched this week in the United States. ABLAVAR (gadofosveset trisodium) is the first MRA injectable imaging agent used to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease (PVD).

In phase 3 clinical studies, ABLAVAR demonstrated statistically greater sensitivity (detecting disease when present) compared with non-contrast MRA. These studies, which supported the FDA approval of ABLAVAR in 2009, show that MRA images using ABLAVAR provided diagnostic accuracy comparable to conventional X-ray angiography,.

The advantages over X-ray angiography include a low dose injection, it does not require catheter insertion into a patient’s arteries, and does not expose patients to ionizing radiation.

“ABLAVAR may provide clinicians performing vascular imaging with more comprehensive, three-dimensional diagnostic information to improve patient treatment decisions and care,” said E. Kent Yucel, M.D., FACR, chairman of radiology, Tufts Medical Center. “ABLAVAR, as the first FDA-approved contrast agent for an MRA indication, is a welcome addition to the currently available options for diagnosing AIOD in patients with known or suspected peripheral vascular disease.”

For more information: www.ablavar.com, www.lantheus.com

Related Content

Iodine-based CT contrast with ready for scanning with a Canon Aquilion One 320-slice CT system at Northwestern Medicine Central DuPage Hospital in the Chicago suburbs. It is not clear that contrast caused contract induced nephrapathy (CIN), also referred to as acute kidney injury (AKI) or contrast-associated acute kidney injury (CAAKI),

Iodine-based CT contrast ready for scanning with a Canon Aquilion One 320-slice CT system at Northwestern Medicine Central DuPage Hospital in the Chicago suburbs.

Feature | Contrast Media | May 31, 2019 | Dave Fornell, Editor
Iodine-based contrast agents used in c
DyeMINISH Multi-center Global Patient Registry Launched
News | Contrast Media | May 09, 2019
Osprey Medical announced the launch of DyeMINISH, a global patient registry to evaluate the ongoing safety and...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...
Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

News | Contrast Media | September 12, 2018
In February 2018, a workshop was held at the National Institutes of Health (NIH) in Bethesda, Maryland, to explore co
Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents
News | Contrast Media | January 19, 2018
Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity....
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media | September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media | August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
Overlay Init